Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.

[1][3] Omidenepag was approved for medical use in Japan in 2018,[3] and in the United States in September 2022.

[2][4] Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.

[1][3] The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.

[6][7] Omidenepag was developed by Ube Industries and Santen Pharmaceutical.